戻る Agenda
Session 1: Patients are waiting: Health Authority regulators, WHO and Industry approaches to accelerate patients’ access to innovation
Session Chair(s)
Catherine Al Ashram
VP Regulatory Affairs & PV, Latin America MEA and Russia
Organon, Jordan
Jeffrey Kemprecos
CGA Director-Gulf
Glaxosmithkline, United Arab Emirates
Session 1: Patients are waiting: Health Authority Regulators, WHO and Industry approaches to accelerate patients’ access to innovation
Speaker(s)
Putting Reliance into Practice: WHO’s Activities on Regulatory Systems Strengthening
Samvel Azatyan, MD, PhD
World Health Organization (WHO), Switzerland
Team Lead, Regulatory Convergence and Networks (RCN/REG)
The ICH perspective
Lenita Lindström, LLM
European Commission, Belgium
ICH Assembly Chair and Senior Expert, European Commission
Access to Innovative Medicines: Study Comparing Regulatory Timelines in 10 Countries in the Middle East & Africa
Mohamed Omar
IQVIA, Egypt
Associate Director
The Reliance Model Implementation in Practice: Examples from Jordan, Saudi Arabia and Egypt - Introduction
Inas Chehimi
Novartis Pharma Services AG, United Arab Emirates
Executive Director - Regulatory & Policy Head - MEA
The Reliance Model Implementation in Practice: Example from Egypt
Heba Nabil
Pfizer, Egypt
Regulatory Affairs Senior Manager
The Reliance Model Implementation in Practice: Example from Jordan
Wesal Al Haqish
Jordan Food and Drug Administration (JFDA), Jordan
Drug Directorate Director
The Reliance Model Implementation in Practice: Example from Saudi Arabia
Bandar Al Hammad, MPharm
Saudi Food and Drug Authority (SFDA), Saudi Arabia
Chief Pharmacist, Regulatory Affairs Department